Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00290134 · ClinicalTrials.gov registry record · Phase 2
A Preliminary Clinical Study to Evaluate Fispemifene in the Treatment of Hypogonadism
A Phase 2 study of Hypogonadism, sponsored by QuatRx Pharmaceuticals Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 16
- Study locations
NCT00290134 is a Phase 2 study of Hypogonadism that has completed, run by QuatRx Pharmaceuticals Company. The registered enrollment target is 100 participants, below the 115-participant average among 21 other Hypogonadism trials with a reported enrollment target (13% lower). The trial reports 16 study locations across 13 states.
The verdict
NCT00290134, a Phase 2 study of Hypogonadism, has completed, sponsored by QuatRx Pharmaceuticals Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this study is to determine whether one or more fispemifene dose regimens are more effective than placebo in the treatment of hypogonadism in older men.
Conditions Studied
Interventions
- DRUG Fispemifene once daily for 4 weeks
Study Locations (16)
New York
- Clinical Research Site - Garden City
- Clinical Research Site - Poughkeepsie
- Clinical Research Site - Williamsville
Florida
- Clinical Research Site - New Port Richey
- Clinical Research Site - Tallahassee
Alabama
- Clinical Research Site - Huntsville
California
- Clinical Research Site - Modesto
Colorado
- Clinical Research Site - Aurora
Connecticut
- Clinical Research Site - Waterbury
Illinois
- Clinical Research Site - Peoria
Maryland
- Clinical Research Site - Greenbelt
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00290134
The ClinicalTrials.gov registry entry for NCT00290134 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 115-participant average among 21 other Hypogonadism trials with a reported enrollment target (13% lower). The listed sponsor is QuatRx Pharmaceuticals Company, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypogonadism appearing as the primary indexed condition, and to 1 intervention - of which Fispemifene once daily for 4 weeks is the first listed.
NCT00290134 reports 16 study locations spanning 13 distinct geographic areas - top geographies include New York, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT00290134 about?
NCT00290134 is a clinical study titled "A Preliminary Clinical Study to Evaluate Fispemifene in the Treatment of Hypogonadism". The purpose of this study is to determine whether one or more fispemifene dose regimens are more effective than placebo in the treatment of hypogonadism in older men.
What is the current status of trial NCT00290134?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2006-02. Estimated completion is 2007-10.
What conditions does trial NCT00290134 study?
This clinical trial studies the following conditions: Hypogonadism.
What interventions are being tested in trial NCT00290134?
The interventions under investigation include: Fispemifene once daily for 4 weeks (DRUG).
Who is sponsoring clinical trial NCT00290134?
This trial is sponsored by QuatRx Pharmaceuticals Company, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00290134 being conducted?
This trial has 16 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypogonadism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury
RECRUITING · Phase 2
-
Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems
COMPLETED · Phase 2
-
Testosterone and Growth Hormone for Bone Loss in Men
COMPLETED · Phase 2
-
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
COMPLETED · Phase 2
-
The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate
COMPLETED · Phase 2
-
Observation of Environment and Reproductive-Endocrine Effects
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.